CTLA4 and cancer: The advent of immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA4), have revolutionized cancer therapy (1–4).